302 patents
Page 10 of 16
Utility
1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE
29 Jul 21
Tord Bertil INGHARDT, Petra JOHANNESSON, Ulrik JURVA, Erik MICHAELSSON, Eva-Lotte LINDSTEDT-ALSTERMARK, Nicholas TOMKINSON, Jeffrey Paul STONEHOUSE, Li-Ming Gan
Filed: 12 Apr 21
Utility
Inducible Modification of a Cell Genome
29 Jul 21
The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
Marcello MARESCA, Mohammad BOHLOOLY-YEGANEH, Himjyot JAISWAL, Lorenz M. MAYR, Xiufeng XU
Filed: 3 Feb 21
Utility
Tetracyclic Heteroaryl Compounds
22 Jul 21
Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Scott Gibson LAMONT, Paul David KEMMITT, Frederick Woolf GOLDBERG
Filed: 7 May 19
Utility
Halo-substituted Piperidines As Orexin Receptor Modulators
15 Jul 21
The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
Filed: 9 Dec 20
Utility
Phenoxyquinazoline compounds and their use in treating cancer
6 Jul 21
Tudor Grecu, Jason Grant Kettle, Martin John Packer, Stuart Eric Pearson, James Michael Smith
Filed: 26 Apr 18
Utility
Inhaler
1 Jul 21
There is disclosed an inhaler 10 for delivery of a medicament by inhalation.
Rune Ducce
Filed: 15 Oct 20
Utility
Fumarate Salt of 5-((5-METHYL-2-((3,4,5-TRIMETHYLPHENYL)AMINO)PYRIMIDIN-4-YL)AMINO)-BENZO[D]OXAZOL-2(3H)-ONE
1 Jul 21
Håkan SCHULZ, Reed Warren SMITH, JR.
Filed: 20 May 19
Utility
Compositions and Methods for Improved Nucleases
1 Jul 21
The present disclosure provides recombinant Cas9 proteins with a faster degradation rate than wild-type Cas9.
ANNA-LINA CAVALLO
Filed: 6 Sep 19
Utility
Tear Lipocalin Muteins Binding IL-4 R Alpha
1 Jul 21
The present invention relates to novel muteins derived from human tear lipocalin, which bind to IL 4 receptor alpha.
Andreas HOHLBAUM, Alexandra Baehre, Gabriele Matschiner, Stefan Trentmann, Klaus Kirchfeld, Hans-Juergen Christian
Filed: 16 Dec 20
Utility
Selective estrogen receptor down-regulators
29 Jun 21
Johannes Wilhelmus Maria Nissink, James Stewart Scott, Thomas Andrew Moss, Samantha Jayne Hughes, Bernard Christophe Barlaam, Bin Yang
Filed: 29 Jan 20
Utility
JAK1 Selective Inhibitors
24 Jun 21
Karl Magnus NILSSON, Annika Birgitta Margareta ÅSTRAND, Anna Ingrid Kristina BERGGREN, Johan R. JOHANSSON, Matti Juhani LEPISTÖ, Sameer Pralhad KAWATKAR, Qibin SU, Jason Grant KETTLE
Filed: 1 Mar 21
Utility
Combination of EGFR Inhibitor and MEK Inhibitor for use in the treatment of NRAS mutated cancer
17 Jun 21
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an E63K NRAS mutation, a G12V NRAS mutation or a gain of copy number of NRAS gene.
Darren Anthony Edward Cross, Catherine Anne Eberlein
Filed: 16 Dec 20
Utility
Compositions and Methods for Improving the Efficacy of CAS9-BASED Knock-in Strategies
17 Jun 21
The present disclosure provides a non-naturally occurring CRISPR-Cas system comprising: a Cas9 effector protein capable of generating cohesive ends (stiCas9), and a guide polynucleotide that forms a complex with the stiCas9 and comprising a guide sequence, wherein the guide sequence hybridizes with a target sequence in a eukaryotic cell but does not hybridize to a sequence in a bacterial cell, and wherein the complex does not occur in nature.
MARCELLO MARESCA, AMIR TAHERI-GHAHFAROKHI, FREDERIK KARLSSON, MOHAMMAD BOHLOOLY-YEGANEH, LORENZ MARTIN MAYR
Filed: 16 Nov 18
Utility
2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators
15 Jun 21
Sarah Lever, Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg
Filed: 13 Jun 18
Utility
Chemical Compounds
10 Jun 21
Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases.
Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
Filed: 17 Jul 20
Utility
Purinone Compounds and Their Use In Treating Cancer
10 Jun 21
Maurice Raymond Verschoyle FINLAY, Frederick Woolf GOLDBERG, Martin Richard HOWARD, Attilla Kuan Tsuei TING
Filed: 14 Jun 19
Utility
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for the Treatment of Cancer
3 Jun 21
The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of cancer, wherein the EGFR TKI is administered in combination with AZD2811.
Nicolas Floch, Paul David Smith, Matthew Joseph Martin
Filed: 11 Nov 20
Utility
Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
20 May 21
Bernard Christophe Barlaam, Kurt Gordon Pike, Andrew John Eatherton, Thomas Anthony Hunt
Filed: 1 Dec 20
Utility
Methods for Preventing or Treating Certain Disorders by Inhibiting Binding of IL-4 And/or IL-13 to Their Respective Receptors
20 May 21
The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof.
Andreas HOHLBAUM, Laurent Audoly, Beverly Koller
Filed: 5 Nov 20
Utility
Selecting Patients for Therapy with Adenosine Signaling Inhibitors
13 May 21
Described herein are measures of the relative expression levels, within a given sample from a subject, of an ACPP transmembrane splice variant to the expression level of one or more ACPP non-transmembrane splice variant(s).
Bolan LINGHU, Melinda MERCHANT, Kris SACHSENMEIER, Mingchao XIE, I
Filed: 23 Apr 19